ALT5 Sigma reported financial results for Q3 2024 ended September 28. Revenue surged to $4.94 million from zero a year ago, driven by the acquisition of ALT5 Subsidiary in May 2024. The company narrowed its net loss to $822,000 from $214,000 in Q3 2023. Gross profit was $2.36 million with a 47.8% margin.The Fintech segment, which includes the newly acquired ALT5 Subsidiary, generated all of the company's revenue and $353,000 in operating income. The Biotechnology segment, focused on developing non-addictive painkillers, incurred $1.57 million in expenses. Selling, general and administrative expenses rose to $3.58 million from $764,000 last year due to the acquisition.As of September 28, ALT5 Sigma had $8.7 million in cash. Management noted the company may require additional financing to fund clinical trials and strategic investments. They also disclosed that disclosure controls were deemed ineffective due to material weaknesses, though steps have been taken to ensure reliable financial reporting.

ALT5 Sigma reported financial results for Q3 2024 ended September 28. Revenue surged to $4.94 million from zero a year ago, driven by the acquisition of ALT5 Subsidiary in May 2024. The company narrowed its net loss to $822,000 from $214,000 in Q3 2023. Gross profit was $2.36 million with a 47.8% margin.The Fintech segment, which includes the newly acquired ALT5 Subsidiary, generated all of the company's revenue and $353,000 in operating income. The Biotechnology segment, focused on developing non-addictive painkillers, incurred $1.57 million in expenses. Selling, general and administrative expenses rose to $3.58 million from $764,000 last year due to the acquisition.As of September 28, ALT5 Sigma had $8.7 million in cash. Management noted the company may require additional financing to fund clinical trials and strategic investments. They also disclosed that disclosure controls were deemed ineffective due to material weaknesses, though steps have been taken to ensure reliable financial reporting.